Hypertension and nephrology

[Application of central sympatholytic agents and vasodilators between 2007-2014 based on OEP’s database]

BARNA István, GYURCSÁNYI András

DECEMBER 10, 2015

Hypertension and nephrology - 2015;19(06)

[Due to the a large number of antihypertensive drugs on the Hungarian market, in the light of the constantly updated recommendations for therapy, seemed to be worth to consider the traffic data provided by the National Health Insurance. We analysed the turnover of the centrally-acting and direct vasodilator antihypertensive, using the data of The National Health Insurance Fund (NHIF) between 2007 and 2014. Every year the December data were comparesed, the turnover of the month did not substantially different from other month, an average of 5-6 million boxes of cardiovascular products are prescribed. Over the past seven years it was fluctuating, but overall there was almost 19% increase in the turnover of centrally acting medicinal products. The prescription number of guanfacine decreased almost one-third, moxonidine orders fell 37%, while the turnover of rilmenidine doubled during that same period. A significant expansion of the centrally acting rilmenidine became clear in the domestic market. The minimal side effects, the favourable profile of applications, the number of international and domestic studies make it an excellent second-third additional agent. The use of vasodilators overall increased of a small degree (15%), mainly due to a 53% increase of doxazosin. Considering the domestic prescribing habits they follow very well the international and domestic recommendations. The observed differences in each group are the effects of the positive results of recent studies.]

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[Measurement Options of Overweight and Obesity and their Levels of Usefulness]

KISS István, KÉKES Ede

Hypertension and nephrology

[The Double-Faced Thiazides]

KEMPLER Péter, HORVÁTH Viktor József

Hypertension and nephrology

[The 11th Hypertension Day in Szolnok]

Hypertension and nephrology

[Role of nephroclinicopathology in the nephrological diagnosis]

NAGY Judit, KEMÉNY Éva, IVÁNYI Béla

[In cases where a definitive diagnosis of a renal disease cannot be established on the basis of the clinical and laboratory data as well as imaging techniques the histological examination of the renal biopsy can be useful for establishing a pathological diagnosis, assessing the prognosis and can give etiopathogenetic information to guide the further management. The description and the degree of the active and chronic changes may influence the rationale treatment and the likelihood of the response. However, discussion between the nephrologist and the nephropathologist is indispensable at the decision to take the biopsy and at the evaluation of the result of the histological examination.]

Hypertension and nephrology

[The Classics of Hypertonology 4. – Professor John H. Laragh, 1924-2015]

KÉKES Ede

All articles in the issue

Related contents

Hypertension and nephrology

[Overview of changes in the use of the cardiovascular system (ATC code based) products based on National Health Insurance data]

GYURCSÁNYI András, BARNA István

[Use of cardiovascular products supported by the National Health Insurance in December 2015 exceeded more than 5% the data of December 2007. This is a significant change, because simultaneously the amount paid as a support decreased by 41.1%. Change in the categories of support resulted in an increase in the use of generics. In addition, the expansion of fixed combinations also brought a significant change in drug consumption. The role of products effecting on the reninangiotensin system, lowering serum lipid modifying agents, diuretics, β-receptor blockers, centrally acting agents and vasodilators in the treatment of cardiovascular diseases has increased as well.]

Hypertension and nephrology

[Trends in the treatment of hypertension]

BARNA István, GYURCSÁNYI András

[Use of drugs treating hypertension (and its associated diseases) supported by the National Health Insurance has changed spectacularly during the last 10 years. In December 2016 the turnover of drugs exceeds almost 2% the data of December 2007. Simultaneously the amount paid as a support decreased by 42.5%. Change in the categories of support resulted in an increase in the use of generics. In addition, the expansion in use of fixed combinations also brought a significant change in drug consumption. During the examined period the role of drugs used in the treatment of hypertension in most the groups has changed.]

Hypertension and nephrology

[About the care of patients with hyperuricaemia and gout]

[This consensus document is intended to provide guidance for the effective and efficient treatment of asymptomatic individuals with high uric acid levels and gout patients.]